全文获取类型
收费全文 | 1762篇 |
免费 | 140篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 25篇 |
妇产科学 | 18篇 |
基础医学 | 278篇 |
口腔科学 | 13篇 |
临床医学 | 168篇 |
内科学 | 544篇 |
皮肤病学 | 35篇 |
神经病学 | 172篇 |
特种医学 | 50篇 |
外科学 | 263篇 |
综合类 | 15篇 |
预防医学 | 84篇 |
眼科学 | 4篇 |
药学 | 88篇 |
中国医学 | 3篇 |
肿瘤学 | 146篇 |
出版年
2024年 | 2篇 |
2023年 | 22篇 |
2022年 | 35篇 |
2021年 | 88篇 |
2020年 | 39篇 |
2019年 | 78篇 |
2018年 | 75篇 |
2017年 | 70篇 |
2016年 | 52篇 |
2015年 | 49篇 |
2014年 | 81篇 |
2013年 | 98篇 |
2012年 | 157篇 |
2011年 | 166篇 |
2010年 | 82篇 |
2009年 | 86篇 |
2008年 | 120篇 |
2007年 | 98篇 |
2006年 | 100篇 |
2005年 | 93篇 |
2004年 | 72篇 |
2003年 | 94篇 |
2002年 | 66篇 |
2001年 | 8篇 |
2000年 | 10篇 |
1999年 | 10篇 |
1998年 | 10篇 |
1997年 | 9篇 |
1996年 | 12篇 |
1995年 | 9篇 |
1994年 | 3篇 |
1993年 | 3篇 |
1992年 | 3篇 |
1991年 | 3篇 |
1990年 | 3篇 |
1989年 | 3篇 |
1988年 | 2篇 |
1986年 | 1篇 |
1980年 | 1篇 |
1976年 | 1篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有1918条查询结果,搜索用时 15 毫秒
991.
992.
993.
Wahl A Praz F Stinimann J Windecker S Seiler C Nedeltchev K Mattle HP Meier B 《Swiss medical weekly》2008,138(39-40):567-572
BACKGROUND: Percutaneous closure of patent foramen ovale (PFO) is generally performed using intra-procedural guidance by transoesophageal (TEE) or intracardiac (ICE) echocardiography. While TEE requires sedation or general anaesthesia, ICE is costly and adds incremental risk, and both imaging modalities lengthen the procedure. METHODS: A total of 825 consecutive patients (age 51 +/- 13 years; 58% male) underwent percutaneous PFO closure solely under fluoroscopic guidance, without intra-procedural echocardiography. The indications for PFO closure were presumed paradoxical embolism in 698 patients (95% cerebral, 5% other locations), an embolic event with concurrent aetiologies in 47, diving in 51, migraine headaches in 13, and other reasons in 16. An atrial septal aneurysm was associated with the PFO in 242 patients (29%). RESULTS: Permanent device implantation failed in two patients (0.2%). There were 18 procedural complications (2.2%), including embolization of the device or parts of it in five patients with successful percutaneous removal in all cases, air embolism with transient symptoms in four patients, pericardial tamponade requiring pericardiocentesis in one patient, a transient ischaemic attack with visual symptoms in one patient, and vascular access site problems in seven patients. There were no long-term sequelae. Contrast TEE at six months showed complete abolition of right-to-left shunt via PFO in 88% of patients, whereas a minimal, moderate or large residual shunt persisted in 7%, 3%, and 2%, respectively. CONCLUSIONS: This study confirms the safety and feasibility of percutaneous PFO closure without intra-procedural echocardiographic guidance in a large cohort of consecutive patients. 相似文献
994.
CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85/p110 heterodimer 下载免费PDF全文
Activation of PI3K is among the earliest signaling events observed in T cells after conjugate formation with antigen-presenting cells (APCs). The relevant PI3K catalytic isoform and relative contribution of the TcR and CD28 to PI3K activity at the immune synapse have not been determined unequivocally. Using a quantitative imaging-based assay, we show that the PI3K activity at the T cell-APC contact area is dependent on the p110delta, but not the p110gamma, isoform of PI3K. CD28 enhanced PIP3 production at the T-cell synapse independently of its YMNM PI3K-recruitment motif that instead was required for efficient PKC recruitment. CD28 could partially compensate for the lack of p110delta activity during T-cell activation, which indicates that CD28 and p110delta act in parallel and complementary pathways to activate T cells. Consistent with this, CD28 and p110delta double-deficient mice were severely immune compromised. We therefore suggest that combined pharmaceutic targeting of p110delta activity and CD28 costimulation has potent therapeutic potential. 相似文献
995.
Fabien Zoulim Jolanta Białkowska-Warzecha Mircea Mihai Diculescu Adrian Eugen Goldis Renate Heyne Tomasz Mach Patrick Marcellin Jörg Petersen Krzysztof Simon Soumaya Bendahmane Isabelle Klauck Wojciech Wasiak Harry L. A. Janssen 《Hepatology International》2016,10(5):779-788
Background and aims
In patients with chronic hepatitis B (CHB) who have failed on other nucleos(t)ide analogs (NUCs), the combination of entecavir (ETV) plus tenofovir disoproxil fumarate (TDF), two potent agents with non-overlapping resistance profiles, may provide a single rescue regimen.Methods
In this single-arm, open-label study, 92 CHB patients with a primary non-response, partial response, or virologic breakthrough on their current NUC were switched to ETV (1 mg) plus TDF (300 mg) and treated for 96 weeks.Results
At baseline, 62 % of patients were HBeAg(+) and mean HBV DNA was 4.4 log10IU/mL. Patients had received ≥1 line of prior NUC therapy, with the latest regimen consisting of monotherapy with ETV (53 %), lamivudine (LVD 22 %), TDF (12 %), adefovir (ADV 4 %), or telbivudine (2 %), or combinations of these agents (7 %); 58 % had evidence of single- or multidrug resistance mutations (LVD 52 %, ETV 26 %; ADV 7 %). Response rates for HBV DNA <50 IU/mL were 76 % (70/92) at week 48 (primary endpoint), and 85 % (78/92) at week 96, including 80 % (16/20) in prior LVD failures, 100 % (4/4) in ADV failures, 82 % (9/11) in TDF failures, and 88 % (42/48) in ETV failures. No treatment-emergent resistance to ETV or ADV was observed. ETV/TDF was well tolerated, with no significant renal or additive toxicities observed.Conclusions
In NUC-experienced patients who have failed prior NUC therapy, ETV/TDF was well tolerated and effective, achieving virologic suppression through 96 weeks in the majority (85 %), irrespective of prior NUC exposure, without occurrence of treatment-emergent resistance to either agent.996.
Coury F Ferraro-Peyret C Le Cam S Guerin S Tebib J Sibilia J Bienvenu J Fabien N 《Clinical and experimental rheumatology》2008,26(2):234-239
OBJECTIVE: The efficacy of anti-tumour necrosis factor-alpha (TNF-alpha) therapies in rheumatoid arthritis (RA) has been mainly attributed to TNF-alpha neutralisation. Other mechanism as immune cell apoptosis, which is impaired in RA, may also be induced by anti-TNF-alpha therapies. The aim of our study was to investigate whether TNF-alpha inhibitors could induce apoptosis in vitro of the peripheral blood lymphocytes of RA patients. METHODS: Peripheral blood mononuclear cells (PBMC) isolated from 24 patients with RA and 18 healthy donors were incubated with anti-TNF-alpha agents, infliximab or etanercept, in comparison with no agent and including an isotypic control, for 48 hours. Apoptosis was detected and quantified by annexin V labelling of phosphatidylserine externalization using cytofluorometric analysis and compared with PBMC production TNF-alpha in vitro. RESULTS: In healthy donors, induced apoptosis was observed in 0.3% to 3.8% of lymphocytes with both therapies. In RA patients the treatment induced lymphocyte apoptosis in 17 of 24 patients with a percentage of annexin V-positive lymphocytes ranging from 0.1% to 25%. Among these 17 RA patients, a significant in vitro lymphocyte apoptosis (> 4%) was observed in 11 patients (46%) compared with healthy donors (p < 0.01). The variability of the response to anti-TNF-alpha within the RA population was not dependent on TNF-alpha synthesis or disease activity. CONCLUSION: In vitro induction of lymphocyte apoptosis by anti-TNF-alpha was observed in a subgroup of RA patients. Based on these data, it would be of interest to further study the interindividual variations of sensitivity to apoptosis induced by TNF alpha inhibitors in relation to treatment efficacy or resistance observed in RA patients. 相似文献
997.
998.
Karen Van den Houte Florencia Carbone Nick Goelen Jolien Schol Imke Masuy Joris Arts Philip Caenepeel Dirk Staessen Philippe Vergauwe Guy Van Roey Pascale Latour Hubert Piessevaux Philippe Maldague Ariane Gerkens Fabien Wuestenberghs Alain Vandenberghe Jan Tack 《Clinical gastroenterology and hepatology》2021,19(8):1620-1626
999.